MRT 67307 dihydrochloride NEW
| Price | $52 | Get Latest Price | Get Latest Price |
| Package | 5mg | 10mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: MRT 67307 dihydrochloride | CAS No.: 1781882-89-0 |
| Purity: 98.43% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | MRT 67307 dihydrochloride |
| Description | MRT 67307 dihydrochloride is a dual inhibitor of the IKKε and TBK-1 with IC50s of 160 and 19 nM, respectively. MRT67307 dihydrochloride also inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively. MRT67307 dihydrochloride also blocks autophagy in cells. |
| In vitro | MRT 67307 dihydrochloride inhibits IKK? and TBK1 with IC50 of 160 and 19 nM when assayed at 0.1 mM ATP in vitro, but did not inhibit IKKα or IKKβ even at 10 μM[1]. MRT 67307 dihydrochloride (2 μM) prevents the phosphorylation of IRF3 in bone-marrow-derived macrophages (BMDMs). MRT 67307 dihydrochloride (2 μM) dose not suppresse the activation of JNK or p38 MAPK by poly(I:C)[1]. MRT 67307 dihydrochloride (1 nM-10 μM) prevents the production of IFNβ in macrophages[1]. MRT 67307 dihydrochloride (10 μM) is sufficient to reduce phospho-ATG13 to control levels[2]. MRT 67307 dihydrochloride (10 μM) blocks autophagy in mouse embryonic fibroblasts (MEFs)[2]. MRT 67307 dihydrochloride (5 μM; 4 h) abrogates TBK1/IKKε-induced CYLD phosphorylation in 293T cells[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 82.8 mg/mL (154 mM) |
| Keywords | MRT 67307 Dihydrochloride | MRT67307 | MRT 67307 dihydrochloride | MRT-67307 | MRT 67307 | MRT-67307 Dihydrochloride | MRT67307 Dihydrochloride |
| Inhibitors Related | YKL-06-061 | Pterosin B | GLPG3970 | ARN-3236 | WH-4-025 | YKL-05-099 | YKL-06-062 | HG-9-91-01 |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Antidepressant Compound Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Neuronal Differentiation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $58.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/1g |
VIP1Y
|
airuikechemical co., ltd.
|
2024-04-07 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY